Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/2 study of BMS-986158 alone or with ruxolitinib or fedratinib in intermediate- or high-risk myelofibrosis
MOH_2021-04-27_009807Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol in myelofibrosis (MF) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability, Maximum tolerated dose and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2021-04-27_009807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-27_009807.